Inclusion Criteria:

- Must be 18 years or older

- Must have a performance status of at least 70% (able to carry on most normal
activities)

- Must have life expectancy of at least 3 months

- Must have adequate organ and marrow function as determined by lab tests

- Women of child-bearing potential and men must agree to use two forms of contraception

- Ability and willingness to sign a written informed consent document

- Histologically confirmed solid tumor malignancy that is metastatic or unresectable

Exclusion Criteria:

- Pregnant or breastfeeding and/or lactating women

- Patients who have received any other investigational agents within 28 days of the
first day of study drug

- Patients with known CNS metastases

- History of other carcinomas within last 5 years (except non-melanoma skin cancer,
in-situ cervical cancer, localized prostate cancer)

- Inadequately controlled hypertension

- Significant vascular disease

- Invasion or encasement of a major artery

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to day 1 of study drug

- Serious illness or medical condition

- History of myocardial infarction, unstable angina, cardiac or other vascular stenting

- History of stroke

- HIV, Hepatitis C, Hepatitis B or other serious chronic infection

- Impairment of Gastrointestinal function or disease

- History of interstitial lung disease

- Patients who have had radiation therapy, hormonal therapy, biologic therapy or
chemotherapy for cancer within 28 days of receiving study drug.